Compare Dell Technologies Inc (DELL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dell Technologies Inc vs BIO-TECHNE Corp — how do they compare? Dell Technologies Inc trades at $583 (market cap $368.11B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Dell Technologies Inc is far larger — about 32.4× BIO-TECHNE Corp's market cap, and Dell Technologies Inc is more actively traded (3,975,387 versus 3,153,511). Which is the better fit depends on your goals — on Pluang, investors hold Dell Technologies Inc for 57 Days and BIO-TECHNE Corp for 63 Days on average.
| DELL | TECH | |
|---|---|---|
Market Cap | $368.11B | $11.37B |
Volume | 3,975,387 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $588.67 | $72.61 |
52-Week Low | $111.10 | $43.31 |
Typical Hold Time | 57 Days | 63 Days |
Enterprise Value | $391.01B | $11.40B |
Dividend Yield | 0.44% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dell Technologies (DELL) trades at $574.74, up 0.16% today, with a bullish technical outlook from moving averages and a consensus analyst price target of $566.35. The stock is buoyed by strong AI server demand, with Q2 2026 EPS of $7.04 beating estimates by 43% and revenue guidance for fiscal 2027 raised to approximately $192 billion. Recent news highlights a 20% dividend increase and a $74 billion AI server backlog, though the RSI suggests mild overbought conditions near resistance at $584.
The outlook for Dell is positive, driven by explosive growth in AI infrastructure orders and robust financial performance. Key opportunities include expanding profit margins and capital returns, while risks involve execution on the large backlog, competitive pressures in the server market, and reliance on continued AI investment trends. The stock's valuation at a P/E of 33.68 reflects high growth expectations.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
